AR028376A1 - Procedimiento para la preparacion de la sal mesilato trihidratada de 1-(4-hidroifenil) -2- (4-hidroxi-4-fenilpiperidin-1-il) -1-propanol - Google Patents

Procedimiento para la preparacion de la sal mesilato trihidratada de 1-(4-hidroifenil) -2- (4-hidroxi-4-fenilpiperidin-1-il) -1-propanol

Info

Publication number
AR028376A1
AR028376A1 ARP010101971A ARP010101971A AR028376A1 AR 028376 A1 AR028376 A1 AR 028376A1 AR P010101971 A ARP010101971 A AR P010101971A AR P010101971 A ARP010101971 A AR P010101971A AR 028376 A1 AR028376 A1 AR 028376A1
Authority
AR
Argentina
Prior art keywords
trihydrated
hydrophenyl
hydroxi
phenylpiperidin
propanol
Prior art date
Application number
ARP010101971A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR028376A1 publication Critical patent/AR028376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
ARP010101971A 2000-04-28 2001-04-26 Procedimiento para la preparacion de la sal mesilato trihidratada de 1-(4-hidroifenil) -2- (4-hidroxi-4-fenilpiperidin-1-il) -1-propanol AR028376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
AR028376A1 true AR028376A1 (es) 2003-05-07

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101971A AR028376A1 (es) 2000-04-28 2001-04-26 Procedimiento para la preparacion de la sal mesilato trihidratada de 1-(4-hidroifenil) -2- (4-hidroxi-4-fenilpiperidin-1-il) -1-propanol

Country Status (27)

Country Link
US (1) US6645986B2 (enExample)
EP (2) EP1151995B1 (enExample)
JP (2) JP3615496B2 (enExample)
KR (1) KR100442718B1 (enExample)
CN (2) CN1590373A (enExample)
AR (1) AR028376A1 (enExample)
AT (1) ATE277014T1 (enExample)
AU (1) AU781436B2 (enExample)
BR (1) BR0101630A (enExample)
CA (1) CA2345582C (enExample)
CZ (1) CZ20011471A3 (enExample)
DE (1) DE60105689T2 (enExample)
DK (1) DK1151995T3 (enExample)
ES (1) ES2227071T3 (enExample)
HK (1) HK1040246B (enExample)
HU (1) HUP0101723A3 (enExample)
ID (1) ID30006A (enExample)
IL (1) IL142705A0 (enExample)
IN (1) IN191027B (enExample)
PL (1) PL347298A1 (enExample)
PT (1) PT1151995E (enExample)
RU (1) RU2203888C2 (enExample)
SI (1) SI1151995T1 (enExample)
TR (1) TR200402696T4 (enExample)
TW (1) TW200505858A (enExample)
YU (1) YU27701A (enExample)
ZA (1) ZA200103320B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7299301A (en) * 2000-06-21 2002-01-02 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7754500B2 (en) 2003-11-21 2010-07-13 Anp Technologies, Inc. Asymmetrically branched polymer conjugates and microarray assays
CA2606815C (en) 2005-05-02 2017-03-07 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
IL122649A (en) * 1995-08-11 2001-08-26 Pfizer (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
SI1151995T1 (en) 2004-12-31
BR0101630A (pt) 2001-12-04
HU0101723D0 (en) 2001-07-30
EP1151995A1 (en) 2001-11-07
CA2345582C (en) 2006-05-30
IL142705A0 (en) 2002-03-10
TW200505858A (en) 2005-02-16
JP2004196823A (ja) 2004-07-15
CN1210262C (zh) 2005-07-13
DE60105689D1 (de) 2004-10-28
YU27701A (sh) 2003-04-30
US6645986B2 (en) 2003-11-11
PL347298A1 (en) 2001-11-05
HK1040246B (zh) 2005-10-28
EP1151995B1 (en) 2004-09-22
AU3889601A (en) 2001-11-01
PT1151995E (pt) 2004-11-30
CZ20011471A3 (cs) 2002-02-13
JP2001354651A (ja) 2001-12-25
KR100442718B1 (ko) 2004-08-02
CN1590373A (zh) 2005-03-09
ZA200103320B (en) 2002-10-24
IN191027B (enExample) 2003-09-13
CN1321638A (zh) 2001-11-14
HK1040246A1 (en) 2002-05-31
ATE277014T1 (de) 2004-10-15
ES2227071T3 (es) 2005-04-01
EP1477479A1 (en) 2004-11-17
CA2345582A1 (en) 2001-10-28
US20020016465A1 (en) 2002-02-07
DE60105689T2 (de) 2005-11-10
ID30006A (id) 2001-11-01
DK1151995T3 (da) 2004-12-13
RU2203888C2 (ru) 2003-05-10
TR200402696T4 (tr) 2004-11-22
KR20010098960A (ko) 2001-11-08
HUP0101723A3 (en) 2003-03-28
HUP0101723A2 (hu) 2002-02-28
JP3615496B2 (ja) 2005-02-02
AU781436B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
PT1320393E (pt) Cassete cirurgica para procedimentos cirurgicos oftalmicos combinados
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
NO20016315D0 (no) Kutteapparat for rörledninger
DE60234471D1 (de) Führung-in-führung-kathetersystem
DE69908701D1 (de) Fungizide Co-Formulierungen
PT1206436E (pt) Retinoides para o tratamento de enfisema
PT1432417E (pt) Compostos de benzimidazole substituído e sua utilização para o tratamento de cancro
FI20000368L (fi) Menetelmä pään alueen kuvaamiseksi
PT1140931E (pt) Antagonistas de 5hti para terapia antidepressiva
AR028550A1 (es) Procedimiento para la obtencion de caprolactama
DK1151995T3 (da) Fremgangsmåde til fremstillingen af mesylatsalttrihydratet af 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
AR028377A1 (es) Procedimiento para la preparacion de la sal mesilato trihidrato de 1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol e intermedios utiles para dicha preparacion
AR028328A1 (es) Proceso para la preparacion de heterociclos benzo-fusionados
EE200300393A (et) Uus besoüülguanidiini sool
PT102287A (pt) Equipamento semi-continuo para granulacao por esferonizacao
AR028400A1 (es) Procedimiento para la preparacion de compuestos halogenados de hidroxidifenilo
EP1598355A4 (en) THERAPEUTIC ACTIVE FOR THE TREATMENT OF SCHIZOPHRENIA
ES1050538Y (es) Estructura mejorada para tabiques de yeso laminar.
ES1047416Y (es) Aislador acustico para techos registrables.
ES1045893Y (es) Pinza para perchas
DE60107973D1 (de) Gewebehandlungszubereitung
AR028548A1 (es) Procedimiento para la obtencion de caprolactama
ES1046576Y (es) Bovedilla para forjados

Legal Events

Date Code Title Description
FB Suspension of granting procedure